A phase 2B, randomized, double blind, placebo-controlled, multicenter study to compare 6 dose regimens of CP-690,550 vs. placebo, each combined with methotrexate, administered for 6 months in the treatment of subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate alone

Trial Profile

A phase 2B, randomized, double blind, placebo-controlled, multicenter study to compare 6 dose regimens of CP-690,550 vs. placebo, each combined with methotrexate, administered for 6 months in the treatment of subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate alone

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Nov 2017 Results (n=2673) of post-hoc analysis assessing the impact of inflammation severity at baseline on efficacy and safety of tofacitinib using pooled data from four phase II trials (NCT00413660, NCT00550446, NCT00603512, NCT00687193) and five phase III trials (ORAL Scan, ORAL Solo, ORAL Sync, ORAL Standard, ORAL Step), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 10 Jun 2017 Biomarkers information updated
    • 01 Feb 2017 Results of post-hoc analysis from pooled data of six phase II studies, six phase III studies and two long term extension studies published in the JCR: Journal of Clinical Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top